share_log

HOOKIPA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Winderlich Mark

HOOKIPA Pharma | 4: Statement of changes in beneficial ownership of securities-Officer Winderlich Mark

HOOKIPA Pharma | 4:持股变动声明-高管 Winderlich Mark
美股SEC公告 ·  04/17 16:20
Moomoo AI 已提取核心信息
Mark Winderlich, Chief Development Officer of HOOKIPA Pharma Inc. (ticker: HOOK), was involved in a transaction with the company's stock on April 15, 2024. The specific details of the transaction, such as the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is essential for investors to understand the implications of the insider's stock activity on their investment decisions.
Mark Winderlich, Chief Development Officer of HOOKIPA Pharma Inc. (ticker: HOOK), was involved in a transaction with the company's stock on April 15, 2024. The specific details of the transaction, such as the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action type and status of the transaction were also not provided. This information is essential for investors to understand the implications of the insider's stock activity on their investment decisions.
2024年4月15日,HOOKIPA Pharma Inc.(股票代码:HOOK)首席开发官马克·温德利希参与了该公司股票的交易。公告中未披露该交易的具体细节,例如股票数量、股票性质、交易价格和股票总价值。也没有提供交易的操作类型和状态。这些信息对于投资者了解内幕人士的股票活动对其投资决策的影响至关重要。
2024年4月15日,HOOKIPA Pharma Inc.(股票代码:HOOK)首席开发官马克·温德利希参与了该公司股票的交易。公告中未披露该交易的具体细节,例如股票数量、股票性质、交易价格和股票总价值。也没有提供交易的操作类型和状态。这些信息对于投资者了解内幕人士的股票活动对其投资决策的影响至关重要。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息